Twist Bioscience Alliance: Antibody Prototyping
IMA seeks to support translational research projects that will develop antibody prototypes by providing access to proprietary technologies from Twist Bioscience.
Stanford and Twist Bioscience have signed a broad agreement enabling Stanford researchers to access Twist’s innovative antibody discovery services as well as its unique “Library of Libraries” for biologics discovery. In exchange for a technology access fee, Stanford researchers can access these libraries through IMA to accelerate antibody discovery against a wide range of therapeutic targets. There’s also an option for researchers to engage Twist in their discovery and optimization work. Stanford will retain all commercial rights with Twist receiving a percentage of downstream licensing revenue share.
Introduction to Twist Bioscience
By leveraging its unique ability to manufacture DNA at scale, Twist can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This “Library of Libraries” provides an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.
Twist’s “Library of Libraries” allows scientists to pan hundreds of libraries against every target. Twist synthetic DNA libraries include the following:
- Hyperimmune libraries
- VHH libraries
- Structural antibody library
- GPCR antibody libraries
- Ion channel library
- Carbohydrate library
Screening of these libraries will be performed in the IMA Protein Therapeutics facilities in order to comply with the above license agreement.
Learn more about the Library of Libraries
In this webinar, Twist Bioscience shares the latest about their Library of Libraries for biologics discovery.
To learn how to access the Twist Bioscience platform, please contact:
Paul Humphries, Ph.D.
Alliance Director, Innovative Medicines Accelerator